Ann Arbor-area start-up Tangent Medical Technologies received a key nod of approval from the Food and Drug Administration to start selling an alternative device to traditional intravenous (IV) drug delivery systems. Scio Township-based Tangent won 510(k) clearance to market a proprietary system called NovaCath, which the company recently showed off for the first time after three years of closely guarded product development. The new closed IV system includes a catheter, extension tubing and a flow control clamp to “eliminate an external ‘j-loop’ based on its redirect of the fluid path internal to the device,” the company said in a news release.
